Intuitive Surgical, Inc.(ISRG) Stock Research - Grey Stern Research

Intuitive Surgical, Inc. (ISRG) Stock Analysis

$580.11 (7.65%)

ISRG Financial Performance


Use the table below to view Intuitive Surgical, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $580.11 -
52 Week Low $355.17 -
52 Week High $584.60 -
Market Cap $206.6 Billion 1/14
Gross Margin 67% 2/14
Profit Margin 28% 1/14
EBITDA margin 28% 2/14
Q3 - 2024 Revenue $2.0 Billion 3/14
Q3 - 2024 Earnings $565.1 Million 1/14
Q3 - 2024 Free Cash Flow $1.5 Million 1/14
Trailing 4 Quarters Revenue $7.9 Billion 3/14
Trailing 4 Quarters Earnings $2.2 Billion 1/14
Quarterly Earnings Growth 36% 7/14
Annual Earnings Growth 34% 5/14
Quarterly Revenue Growth 17% 3/14
Annual Revenue Growth 12% 2/14
Cash On Hand $2.4 Billion 1/14
Short Term Debt $0 14/14
Long Term Debt $0 14/14

Intuitive Surgical, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Intuitive Surgical, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 92.11 2/14
PS 26.26 1/14
PB 13.18 1/14
PC 85.62 2/14
Liabilities to Equity 0.13 13/14
ROA 0.13 3/14
ROE 0.14 4/14
Current Ratio 8.59 1/14
Quick Ratio 2.05 1/14
Long Term Debt to Equity 0.00 13/14
Debt to Equity 0.00 13/14
Burn Rate -4.27 11/14
Cash to Cap 0.01 12/14
CCR 2.63 3/14
EV to EBITDA 353.73 3/14
EV to Revenue 25.96 1/14

Company Details

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

CEO: Dr. Gary Guthart

Website: https://www.intuitive.com

Address: 1020 Kifer Rd Sunnyvale, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

Intuitive Surgical, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Intuitive Surgical, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $67.5 Billion
Hologic, Inc. HOLX $15.6 Billion
Baxter International Inc. BAX $15.4 Billion
ResMed Inc. RMD $34.3 Billion
The Cooper Companies, Inc. COO $18.1 Billion
Teleflex Incorporated TFX $8.2 Billion
West Pharmaceutical Services, Inc. WST $23.8 Billion
Merit Medical Systems, Inc. MMSI $5.9 Billion
ICU Medical, Inc. ICUI $4.1 Billion
Repligen Corporation RGEN $8.8 Billion
Bionano Genomics, Inc. BNGO $27.8 Million
NEXGEL, Inc. NXGL $25.9 Million
Embecta Corp. EMBC $1.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ISRG Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 2.0 Billion $565.1 Million
Q2 2024 $ 2.0 Billion $526.9 Million
Q1 2024 $ 1.9 Billion $544.9 Million
Q4 2023 $ 1.9 Billion $606.2 Million
Q3 2023 $ 1.7 Billion $415.7 Million
Q2 2023 $ 1.8 Billion $420.8 Million
Q1 2023 $ 1.7 Billion $355.3 Million
Q4 2022 $ 1.7 Billion $324.9 Million

View All

ISRG Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $2.4 Billion $17.7 Billion $0 $15.7 Billion
Q2 2024 $3.0 Billion $16.6 Billion $0 $14.8 Billion
Q1 2024 $2.8 Billion $15.8 Billion $0 $14.0 Billion
Q4 2023 $2.8 Billion $15.4 Billion $0 $13.4 Billion
Q3 2023 $3.6 Billion $14.7 Billion $0 $12.5 Billion
Q2 2023 $3.4 Billion $13.9 Billion $0 $12.0 Billion
Q1 2023 $371.4 Million $13.1 Billion $0 $11.3 Billion
Q4 2022 $1.6 Billion $13.0 Billion $0 $11.1 Billion

View All

ISRG Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $1.5 Billion $551.3 Million -$590.4 Million
Q2 2024 $311.1 Million -$309.4 Million $197.2 Million
Q1 2024 -$203.1 Million -$241.9 Million $89.4 Million
Q4 2023 -$207.2 Million -$435.5 Million -$852.8 Million
Q3 2023 $574.0 Million $0 $651.4 Million
Q2 2023 $487.4 Million -$178.3 Million $1.3 Billion
Q1 2023 $177.3 Million -$194.1 Million $565.1 Million
Q4 2022 $300.2 Million -$137.7 Million $46.7 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions